10 closest matches · ranked by relevance
Toxic Shock Syndrome
Primary: Number of Participants (Percentage) With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment — 9; 11; 11; 12 Participants
Toxic Shock Syndrome · Vaccination; Sepsis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 1; 1; 2; 7 participants with any solicited AE
Toxic-Shock Syndrome · Sepsis
Primary: Number of Participants With Adverse Events as a Measure of Safety — 7; 1; 1; 0 participants
Nonmalignant Breast Conditions · Breast Cancer
Primary: Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week — 10; 21 participants — p=0.02
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Vaginal Microflora
Primary: Percentage of Subjects Showing Unfavorable Changes in Primary Microflora — 52.7; 52.9; 60.0 Percentage of Participants
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001